Page 169 - Biomarkers for risk stratification and guidance in heart failure

Chapter 7
63. Meta-analysis Global Group in Chronic Heart F. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. European heart journal 2012;33:1750-7.
64. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? Journal of the American College of Cardiology 2012;60:2349-56.
65. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European heart journal 2006;27:2338-45.
66. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. The New England journal of medicine 2014;370:1383-92.
67. Authors/Task Force M, Document R. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure 2016.
68. van Deursen VM, Urso R, Laroche C, et al. Comorbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. European journal of heart failure 2014;16:103-11.
69. Mastromarino V, Casenghi M, Testa M, et al. Polypharmacy in heart failure patients. Current heart failure reports 2014;11:212-9.
70. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical therapeutics 2001;23:1296-310.
71. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998;80:437-41.
72. Lenzen MJ, Boersma E, Reimer WJ, et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. European heart journal 2005;26:2706-13.
73. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2013;62:e147-239.
74. Felker GM, Ahmad T, Anstrom KJ, et al. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. JACC Heart failure 2014;2:457- 65.
75. Adlbrecht C, Huelsmann M, Berger R, et al. Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care. European journal of clinical investigation 2011;41:315-22.
76. Morimoto T, Hayashino Y, Shimbo T, Izumi T, Fukui T. Is B-type natriuretic peptide-guided heart failure management cost-effective? International journal of cardiology 2004;96:177-81.
77. Sanders-van Wijk S, van Asselt AD, Rickli H, et al. Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure). JACC Heart failure 2013;1:64-71.
78. Januzzi JL, Jr., Sakhuja R, O’Donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Archives of internal medicine 2006;166:315-20.
79. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino- terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clinical chemistry 2006;52:1528-38.
80. Bayes-Genis A, Pascual-Figal D, Fabregat J, et al. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. International journal of cardiology 2007;120:338- 43.
81. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. Journal of cardiac failure 2001;7:21-9.
82. Felker GM, O’Connor CM, Braunwald E, Heart Failure Clinical Research Network I. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circulation Heart failure 2009;2:56-62.
168